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Abstract: a new multipurpose voice analysis tool 
named biovoice2, suited for the analysis of strongly 
irregular signals and long sentences, is applied on 
voices of patients diagnosed with adductor spasmodic 
dysphonia before and after treatment with botulinum 
toxin injection. the speech material consists of 40 
short German sentences phonetically selected to be 
constantly voiced. nine acoustic parameters were 
taken into account from all those estimated with 
biovoice2. significant improvement of voice quality 
was estimated by a subset of these parameters related 
to increased voicing, improved regularity of vocal fold 
vibration, reduction of spasms and faster speech rate. 
biovoice2 proves to be a useful tool for objectifying 
voice quality also in case of strong signal irregularity.   
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Spasmodic dysphonia (SD) is a particular voice 
disorder characterized by involuntary movements of one 
or more muscles of the larynx during speech.  
The most common form of this pathology is the adductor 
SD (ADSD) that is considered in this study. The ADSD is 
expressed with different severity from case to case, from 
mild cases that present only a slight tremor of the voice 
and occasional breaks to cases where severe spasms of 
the vocal cords make it impossible to speak, preventing 
airflow through the glottis. In such cases the patient’s 
work and social life are compromised and this can also 
frequently lead to severe depression [1]. 
With (AD)SD, deviant acoustic events as aperiodicity, 
phonatory breaks and frequency shifts perturb fluency 
and intelligibility. These voices thus require specific 
acoustic parameters for an exhaustive analysis [2-4].  
The present study is based on a new multipurpose voice 
analysis tool, named BioVoice2, developed under 
MatLab environment, capable to deal with highly 
irregular voice signals as those under study.  
The aim of the present study is to test the ability of 
BioVoice2 to evaluate the improvement in patient’s voice  
 
 
quality using objective parameters and, accordingly, the 
effectiveness of the medical treatment that consist of 




Currently most of the software tools for voice analysis 
have limitations related to the level of irregularity in the 
voice and to their applicability to running speech instead 
of sustained vowels only [5]. To overcome these 
limitations, we designed a multipurpose program, 
BioVoice 2 that is applicable to the analysis of a wide 
range of voice signals, including the analysis of long 
sentences (several minutes of connected speech) other 
than short ones or sustained vowels only.  
The main targets in designing BioVoice 2 were: 
 
 Implementing a robust and reliable fundamental 
frequency (F0) estimation and a Voiced/Unvoiced 
(V/U) selection procedure, applicable to quasi-
stationary/noisy signals such as highly hoarse, 
irregular voices and/or sentences; 
 
 Allowing for the analysis of long sentences (several 
minutes) other than short ones or sustained vowels 
only; 
 
 Giving the user a simple Graphic User Interface 
(GUI) that does not require any manual setting by the 
user, thus being well suited also for non-expert users.   
 
BioVoice 2 performs the analysis of audio files resulting 
in objective parameters that are considered useful by 
clinicians in the diagnosis of voice disorders. It has been 
successfully tested on synthesized sustained vowels 
giving better results than most commonly used software 
tools when applied to strongly irregular and hoarse voice 
signals [9]. The main parameters of interest in the present 
work are: 
 
f0: the fundamental frequency is estimated with a two 
steps procedure. First, Simple Inverse Filter Tracking is 
performed, obtaining a raw F0 estimation and its range of 
variation         where   = lowest F0 value and    = 
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highest F0 value. In the second step, F0 is estimated 
inside         with the Average Magnitude Difference 
Function (AMDF) approach [9]. The program provides 
F0 tracking and its mean, standard deviation, minimum 
and maximum values. 
pvf: the ratio between the number of voiced frames and 
the total number of frames, that depends on the breaks 
which are present in the voice: the more the pauses, the 
less the PVF.  
pvs: the percentage of voiced speech frames, which 
means the ratio of voiced frames over the frames that 
have been classified as speech in a previous step of 
analysis. Speech frames are those in which the zero 
crossing rate is less than 3000 zero-crossings per 
milliseconds and the energy exceeds a threshold value 
that depends on the signal characteristics. Hence PVS 
should be higher or equal to PVF. On a sustained vowel 
and for a healthy voice, PVS is ideally 100%. As a 
general rule the better the voice, the higher both PVF and 
PVS.  
pfu: the percentage of frames that have an unreliable F0 
among the total number of frames. This parameter is 
therefore a measure of the fundamental frequency F0 
instability. Frequency variations make F0 unstable. In a 
frame F0 is evaluated as unreliable if it has a deviation of 
more than 25% compared to the average F0 value over all 
voiced frames. In this case the better the voice, the lower 
the PFU percentage. 
vl90: the 90th percentile of voicing length distribution, 
defined as the maximum number of consecutive voiced 
frames found. The sharp breaks featuring the voice of 
patients with SD reduce this parameter.  
duration: the total time required to the patient for 
pronouncing sentences. As a general rule a healthy voice, 
that is more fluent, will have a shorter duration than a 
pathological one.  
In addition BioVoice 2 evaluates the time duration of the 
voiced and unvoiced part of the signal, and the average 
length of voiced frames (mean duration of voicing, 
Mdv). 
Jitter: a measure of the degree of variability of the period 
length. It gives a measure of the aperiodicity of the signal 
measuring the changes in fundamental period T0=1/F0 
from period to period.  Of course, good voices have low 
jitter.  Jitter J is evaluated here according to Eq.1:                          




  Where N is the number of frames and Ti is the i-th 
period length.                                     
corrected jitter: the correction means that only frames 
with reliable F0 are taken in account. F0 is reliable if it 
has less than 25% deviance from the mean value of F0 of 
all voiced frames. The formula for Corrected jitter is the 
same as for the jitter. 
nne: Normalized Noise Energy is a noise estimation 
method that relies on a comb filtering approach: it is the 
ratio of the energy between the harmonics and the whole 
signal energy [8]. 
Moreover, BioVoice2 allows for the estimation of the 
signal spectrogram, formants, Power Spectral Density 
and other parameters related to the kind of voice signal 
under analysis (adult male, adult female, newborn cry and 
singing voice) that are not described here. Plots and 
tables can be displayed, printed and saved in an easy way. 
Details can be found in [5]. 
To test the capability of BioVoice2 of analyzing long 
sentences in a reliable way, 24 audio files (12 pre- and 12 
post-treatment) from 12 German patients diagnosed with 
ADSD are considered here. Each patient read a 
standardized list of 40 German sentences for a total 
duration of about 2’30”. These sentences are phonetically 
selected by clinicians for being constantly voiced. This is 
in fact supposed to increase the sensitivity for detecting 
interruptions of vocal fold vibrations induced by SD.  
Audio files are provided in uncompressed audio wave 
format with sampling frequency Fs= 44.100 Hz and 16 
bit of resolution. All the recordings were made in a quiet 
room by one of the authors of this work. 
 
III. EXPERIMENTAL RESULTS 
 
Table 1 reports the mean value of the parameters 
previously described, obtained from pre and post-
treatment recordings. From Table 1 a clear trend towards 
better voice quality is shown (post-treatment values 
higher or lower than pre-treatment ones, according to the 
specific parameter). 
 
Table 1 – Mean value of the acoustic parameter computed 
by BioVoice2. 
parameter  pre post 
pvf % Mean 51.80 69.45 
pvs % Mean 52.82 69.54 
pfu % Mean 50.29 44.81 
Jitter % Mean 14.63 13.76 
corrected Jitter % Mean 6.12 6.24 
vl90 [s] Mean 0.0008 0.0160 
duration [s] Mean 142.07 137.68 
Mdv [s] Mean 0.277 4.03 
nne [db] Mean -17.49 -17.58 
Mean f0 [hz] Mean 180.65 188.62 
std f0 [hz] Mean 46.05 50.05 
 
These results show that the parameters PVF, PVS, VL90 
as well as MDV are strongly indicative of voice 
improvement, while for the other parameters the pre-post 
difference seems less significant.  
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Figure 1 shows the difference between pre- and post-
treatment values of the most relevant acoustic parameters 




Fig. 1: Upper: mean value of VL90 and MDV (seconds). 
Lower: mean value of PVF, PVS, PFU (%) for pre-post 
treatment data. 
 
Moreover the Wilcoxon test was applied on each 
parameter separately. Results are reported in Table 2. 
 

















As expected, only few of the acoustic parameters reveal a 
significant post- vs. pre- improvement. Specifically these 
parameters are: PVF, PVS, VL90 and MDV. In particular 
Jitter, Corrected jitter, PFU, NNE and even duration show 
no statistically significant differences and are thus not 
suited for evaluating the improvement of voice quality 
with the present data. As these parameters have different 
measurements units and ranges a standardization step was 
performed according to the following equation [7]: 






Where    is the variable to be standardized,  ̅ is its mean 
value and   is its standard deviation.  
Figure 2 shows the boxplot of pre- post-treatment data for 
all the acoustic parameters considered here. On each box, 
the central mark is the median, the edges of the box are 
the 25th and 75th percentiles respectively, and the 
whiskers extend to the most extreme data points that are 
not considered outliers. The small circles are the outliers. 
Data are standardized according to Eq.2.  
The plot confirms the best results obtained with 
parameters PVF, PVS, VL90 and MDV.  
   
IV. DISCUSSION 
 
Results in Table 2 show that only four of the whole 
acoustic parameters considered here are capable to point 
out a significant post- vs. pre-treatment improvement in 
voice quality. These parameters are all related to the 
increased voicing capability of the patient after medical 
treatment.  
Hence only the acoustic parameters that are in some way 
related to the selection of voiced/unvoiced parts of the 
signal are successful in the analysis of a long sentence, 
while other, and also jitter, seem to have less relevance. 
This result suggests that a different analysis should be 
performed on fluent speech other than that usually made 
on sustained vowels or short sentences.  
Results are in agreement with previous studies made on 
the same speech material where a different analysis 
program was used [7]. However, differently from [7], 
with BioVoice2 more parameters, such as a noise 
measure, F0 and its standard deviation can be included in 
the analysis.   
Moreover, a new parameter was introduced here for the 
first time, namely the mean duration of voiced frames, 
MDV. From the preliminary results presented here (Table 
1 and Table 2), this parameter seems indeed to be very 





A new multipurpose voice analysis tool is presented 
here and its performance is evaluated on fluent speech 
coming from patients affected by adductor spasmodic 
dysphonia. Even if the data set consists of a limited 
number of patients, significant changes in the value of 
acoustic parameters were found comparing the pre- and 
post-treatment recordings, pointing out the improvement 
of voice quality after botulinum toxin treatment. Some 
parameters such as jitter, already proved valid in the 
analysis of short sentence or sustained vowels, seem to 
lose meaningfulness when evaluated on long sentences. 





















fundamental frequency instability, seem to lose its 
capability in evaluating the voice signal in long 
sentences.  
However, the proposed tool is successful in objectifying 
the increased voicing and the improved regularity of 
vocal fold vibration after treatment. One newly defined 
parameter, the mean value of voiced frame duration, 
seems very promising in evaluating voice quality 
improvement when applied to long sentences. Future 
work will be devoted to refining the tool in order to 
reduce the computational time while preserving its high 
resolution capabilities and robustness against noise. The 
tool will be also tested on a new corpus of synthetic 
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Fig. 2: Boxplot of pre-post treatment acoustic parameters. 
